Document is current
Any future updates will be listed below
-
Authors
Guièze, Romain https://orcid.org/0000-0001-7563-580X
Ysebaert, Loïc
Roos-Weil, Damien https://orcid.org/0000-0002-7767-755X
Fornecker, Luc-Mathieu
Ferrant, Emmanuelle
Molina, Lysiane
Aurran, Thérèse
Clavert, Aline
de Guibert, Sophie
Michallet, Anne-Sophie
Saad, Alain
Drénou, Bernard
Quittet, Philippe
Hivert, Bénédicte
Laribi, Kamel
Gay, Julie https://orcid.org/0009-0006-8923-6010
Quinquenel, Anne
Broseus, Julien
Rouille, Valérie
Schwartz, David
Magnin, Benoit https://orcid.org/0000-0002-4246-5688
Lazarian, Grégory
Véronèse, Lauren
de Antonio, Marie
Laurent, Camille
Tournilhac, Olivier https://orcid.org/0000-0002-9438-621X
Pereira, Bruno
Feugier, Pierre
- License Information
-
More Information
Article History
Received: 19 February 2024
Accepted: 3 August 2024
First Online: 9 August 2024
Competing interests
: R.G. reports research grants from Amgen, AstraZeneca, Roche, Janssen, Abbvie, and BeiGene; consulting fees; honoraria; and travel funds from AstraZeneca, Roche, Janssen, Abbvie, and BeiGene. J.G. reports consulting fees, honoraria, and travel funds from AstraZeneca, Janssen, Sanofi. E.F. reports consulting fees, honoraria, and travel funds from AstraZeneca, Janssen, Abbvie, and BeiGene. A.C. reports consulting fees, honoraria and travel funds from AstraZeneca, Roche, Janssen, and Abbvie. J.B. reports honoraria from AstraZeneca and Janssen, and travel funds from AstraZeneca and Abbvie. K.L. has received research grants from AbbVie, AstraZeneca, Novartis, BeiGene, Amgen, as well as personal fees from AbbVie, Novartis, BMS, BeiGene, Takeda, Janssen, AstraZeneca, and Amgen. P.F. reports, consulting fees, honoraria, and travel funds from AstraZeneca, Roche, Gilead, Janssen, BeiGene, and Lilly. The remaining authors declare no competing interests.
